#United States #MD Anderson #Research Triangle Park #Bantam Pharmaceutical #BTM-3566

Bantam Pharmaceutical Launches First Clinical Trial Site at MD Anderson Cancer Center

In a significant advancement in cancer treatment, Bantam Pharmaceutical has announced the activation of its first Phase 1 clinical trial site at the prestigious MD Anderson Cancer Center. This trial is set to evaluate the efficacy of BTM-3566, a pioneering cancer therapeutic specifically designed to target relapsed and refractory mature B-cell lymphomas.

BTM-3566 is categorized as a first-in-class small molecule therapy that works by modulating mitochondrial dynamics through the ATF4-Integrated Stress Response (ISR) pathway. This innovative approach is expected to provide targeted treatment options for patients suffering from aggressive tumors, thereby offering a new ray of hope in the fight against cancer.

Michael Stocum, the President and CEO of Bantam Pharmaceutical, expressed his enthusiasm regarding the partnership with MD Anderson, stating, “This represents a major milestone for our company as we transition from discovery into clinical development.” He highlighted the importance of collaboration with an institution renowned for its pioneering research and innovation in oncology. Stocum emphasized that BTM-3566 aims to combine the tumor-killing potency of traditional chemotherapy while providing the precision and selectivity characteristic of breakthrough targeted therapies.

The Phase 1 clinical trial is a multicenter, open-label study that will undergo dose-escalation and expansion phases. It will focus on assessing various aspects, including the safety, tolerability, pharmacokinetics, and anti-tumor effects of BTM-3566. Initial results from the trial are anticipated in the latter half of 2025, marking a crucial step in determining the treatment's viability for patients.

As a part of its commitment to combating critical oncology challenges, Bantam Pharmaceutical is dedicated to expanding the clinical trial further to additional sites across North America in the upcoming months. This expansion illustrates the growing need for novel treatments targeting such aggressive tumor types, which have previously shown resistance to standard therapies.

Overview of BTM-3566

BTM-3566 is structured as an orally administered small molecule aimed at a diverse range of cancers, particularly focusing on hematologic malignancies and solid tumors. The immediate clinical target remains mature B-cell lymphomas, including mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL).

In preclinical assessments, BTM-3566 has exhibited robust anti-cancer properties, leading to significant tumor reduction and, in many scenarios, complete tumor eradication in models resistant to conventional treatment methods, including CAR-T cell therapy. Its operational mechanism revolves around disrupting mitochondrial functions within tumor cells, effectively triggering apoptosis, or programmed cell death, thereby facilitating cancer management.

Bantam Pharmaceutical is not only eyeing B-cell malignancies but is also strategizing to extend its clinical development into solid tumors, aiming to broaden the therapeutic impact for patients facing limited treatment alternatives. This dual focus represents Bantam’s innovative spirit and commitment to tackling one of the most pressing health challenges.

About Bantam Pharmaceutical

Bantam Pharmaceutical, based in Research Triangle Park, North Carolina, is dedicated to drug discovery and development, particularly in oncology. With a strong emphasis on mitochondrial dynamics, Bantam aims to fulfill unmet medical needs through novel, first-in-class oral therapeutics that target difficult-to-treat cancers.

The company currently maintains an active Investigational New Drug (IND) application in the United States and a Clinical Trial Application (CTA) in Canada for BTM-3566. For further information regarding the clinical trial details, interested parties can visit ClinicalTrials.gov and search using the NCT number NCT06792734.

For more insights into Bantam Pharmaceutical and its innovative projects, visit their official website at Bantam Pharmaceuticals.